Pelthos Therapeutics Expands ZELSUVMI Formulary to 127M Lives

Pelthos Therapeutics Inc. has expanded its ZELSUVMI formulary access to 127 million commercially covered lives. This follows a recent agreement with a major PBM that added 24 million covered lives and a regional plan update of approximately 3 million lives. The PBM added coverage without prior authorization, effective October 1, 2026.